

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Tocilizumab for treating giant cell arteritis

Batch 52

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping process, it was noted that giant cell arteritis is more common in older people; the mean age at diagnosis is 76 years and condition is rare in people aged below 50 years. It was also noted that sight loss is a complication of giant cell arteritis, the risk of which increases in people with pre-existing conditions such as complicated diabetes or chronic infections.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will make recommendations which apply equally regardless of age, so a difference in disease prevalence by age does not in itself represent an equality issue. The committee will consider whether its recommendations could have a differential impact on people with conditions which pre-dispose them to sight loss.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): ...Janet Robertson...

Date: 02 June 2017